+

US20110201601A1 - Inhibitors of the shiga toxins trafficking through the retrograde pathway - Google Patents

Inhibitors of the shiga toxins trafficking through the retrograde pathway Download PDF

Info

Publication number
US20110201601A1
US20110201601A1 US12/999,749 US99974909A US2011201601A1 US 20110201601 A1 US20110201601 A1 US 20110201601A1 US 99974909 A US99974909 A US 99974909A US 2011201601 A1 US2011201601 A1 US 2011201601A1
Authority
US
United States
Prior art keywords
group
toxin
benzo
diazepin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/999,749
Other versions
US8609732B2 (en
Inventor
Daniel Gillet
Julien Barbier
Ludger Johannes
Bahne Stechmann
Siau-Kun Bai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Curie
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Curie
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Curie, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Centre National de la Recherche Scientifique CNRS
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, INSTITUT CURIE reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JOHANNES, LUDGER, BARBIER, JULIEN, GILLET, DANIEL, BAI, SIAU-KUN, STECHMANN, BAHNE
Publication of US20110201601A1 publication Critical patent/US20110201601A1/en
Priority to US14/083,690 priority Critical patent/US9034868B2/en
Application granted granted Critical
Publication of US8609732B2 publication Critical patent/US8609732B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/16—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring not being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/02—Thiourea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/46—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing nine carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the use of imine and benzodiazepine derivatives as therapeutic agents, particularly in the treatment of disorders caused by Shiga toxins.
  • Shigella dysenteriae some strains of Escherichia coli as well as other bacteria can secrete Shiga toxins (Stxs), which cause serious complications and deaths during infections.
  • Shiga toxins Shiga toxins
  • Shiga toxin producing pathogens involved in sporadic cases and outbreaks of disease.
  • Shiga toxin producing bacteria are associated with a broad spectrum of clinical manifestations in humans ranging from asymptomatic colonization to life threatening hemolytic uremic syndrome (HUS) (Tarr et al. (2005). Lancet 365, 1073-1086).
  • HUS hemolytic uremic syndrome
  • STEC infection may be asymptomatic, it typically begins with an onset of watery diarrhea between 2 and 12 days after STEC ingestion and is frequently associated with abdominal pain and occasionally with nausea and vomiting (Tarr et al., 2005). Watery diarrhea lasts for 1-3 days after which, in 90% of the cases, it progresses to bloody diarrhea (Tarr at al., 2005). Then approximately 15% of the STEC-infected subjects develop HUS.
  • HUS microangiopathic hemolytic anemia (with fragmented red blood cells: schistocytes), thrombocytopenia and nephropathy.
  • Other extra-renal complications of HUS may also subsequently occur such as seizures, intracranial infarction or hemorrhage, retinal hemorrhage and encephalopathy, acute pancreatitis, cardiomyopathy and death (in ⁇ 4%) (Elliott, E. J., and Robins-Browne, R. M. (2005). Curr Probl Pediatr Adolesc Health Care 35, 310-330).
  • STEC infections do not require medical care, a small percentage of cases develop HUS with after-effects such as chronic kidney failure requiring lifelong dialysis or a kidney transplant.
  • Shiga toxins belong to the toxins that use the cell retrograde transport; these toxins include ricin (produced in the seeds of the castor oil plant Ricinus communis ), Shiga and Shiga-like toxins (Stx1 and Stx2, together designated Stxs, produced by Shigella dysenteriae and E. coli ), cholera toxin (Ctx produced by Vibrio cholerae ), heat-labile enterotoxin (produced by E. coli ), pertussis toxin (produced by Bordetella pertussis ), and subtilase cytotoxin (produced by E. coli ). These toxins share a similar structural organization: a receptor-binding B-subunit associated with a catalytic active A-subunit.
  • toxins After binding to their target cell receptors, these toxins are internalized and transported to early endosomes (EE). Instead of being recycled back to the plasma membrane or transported to late endosomes/lysosomes for degradation, an important number of toxin molecules gain access to the Golgi apparatus and the endoplasmic reticulum (ER), from where their A-subunits are retro-translocated into the cytosol (Sandvig et al. (2002) Annu. Rev. Cell Dev. Biol. 18:1-24).
  • EE early endosomes
  • the A-subunits of Stxs toxins and ricin remove a conserved adenine-residue from ribosomal RNA, leading to an inhibition of protein biosynthesis and apoptosis, whereas the A-subunit of cholera toxin modifies the stimulatory G-protein G s ⁇ , causing the untamed, constitutive production of the secondary messenger cAMP, which finally provokes a dramatic efflux of ions and water from the digestive track.
  • this analog is composed of silicon dioxide particles covalently linked to the trisaccharide moiety (globotriose [ ⁇ -D-Gal-(1 ⁇ 4)- ⁇ -D-Gal-(1 ⁇ 4)-D-Glc]) of the globotriaosylceramide molecule that mediates Shiga toxin binding; it was the first compound that was tested in humans (Synsorb Pk, see Armstrong et al., 1995). Synsorb Pk was designed to trap and eliminate free Stxs produced in the gut of patients infected by Stx-producing E.
  • Stx inhibitors containing trisaccharides, have also been described for their ability to protect animals.
  • Another approach aims at inactivating the catalytic active A-subunit of the toxin (StxA).
  • these compounds are rather unspecific, as they affect the morphology of cellular compartments. Their effect is thus not restricted to the retrograde transport pathway (the anterograde/biosynthetic transport is affected, too) or to these toxins (the transport of endogenous proteins is affected as well). Treatment is most likely not possible without causing severe side effects.
  • the inventors have found that unexpectedly the compounds of formula (I) (imine derivatives) and the compounds of formula (II) (benzodiazepine derivatives) are efficient for preventing and/or treating Shiga toxins cells intoxications.
  • the present invention relates to the use of an imine derivative of formula (I):
  • X is —NH— or —O—
  • R 1 is a cycloalkyl radical having 5 to 10 carbon atoms, having one or two rings, saturated or not, wherein one or more carbon atom may be replaced by a nitrogen, oxygen or sulfur atoms; said cycloalkyl radical being optionally substituted by one or more groups chosen amongst a halogen atom, a hydroxyl function, a nitro function and a C 1 -C 3 alkyl group,
  • R 2 is a hydrogen atom or a link; when R 2 is a link, then the nitrogen atom forms a double bond with the adjacent carbon atom;
  • Shiga toxins and related toxins include the Shiga toxin (Stx) produced by Shigella dysenteriae, Shiga-like toxin 1 and 2 (SLT-1 and 2 or Stx-1 and 2 or Verotoxin 1 and 2) produced by Shigatoxigenic group of Escherichia coli (STEC), which includes serotype O157:H7 and other enterohemorrhagic E. coli and cholera toxin (Ctx).
  • HUS hemolytic uremic syndrome
  • the present invention also relates to pharmaceutically acceptable salt of compounds of formula (I) such as hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen, acetate, oxalate, benzoate, succinate, fumarate, maleate, lactate, citrates, tartrate, gluconate, methanesulphonate, benzene-sulphonate and paratoluene-sulphonate.
  • pharmaceutically acceptable salt of compounds of formula (I) such as hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen, acetate, oxalate, benzoate, succinate, fumarate, maleate, lactate, citrates, tartrate, gluconate, methanesulphonate, benzene-sulphonate and paratoluene-sulphonate.
  • halogen atom is meant the chemical elements of group VII of the periodic table of elements; including fluorine, chlorine, bromine and iodine.
  • the preferred halogen is bromine (Br) and fluorine (F).
  • C 1 -C 3 alkyl group means a linear or branched chain of 1 to 3 carbon atoms; said chain may be for example methyl, ethyl, propyl or isopropyl.
  • the preparation of said imine derivatives is achieved by adding a solution of an amine in methanol to an aldehyde, said amine and aldehyde being chosen according to the imine derivative to prepare, and the mixture is stirred for 2 days.
  • the imine derivatives are obtained after evaporation and purification.
  • the evaporation is performed as follows: a solution of imine in methanol is added on BH 3 CN resin (3 equiv.) and AcOH. After 3 days at room temperature (15-25° C.), the mixture is filtered, washed with methanol and then concentrated under vacuum. The crude compound thus obtained is purified by conventional methods.
  • the present invention also relates to the use of a benzodiazepine derivative of formula (II):
  • R 3 is chosen amongst a hydrogen atom, a halogen atom, a C 1 -C 6 alkyl group, a C 1 -C 6 alcoxy group, a C 1 -C 6 acyloxy group, an aryloxy group, a heteroaryloxy group; these groups being optionally substituted by a C 1 -C 6 alcoxy group or a heteroaryloxy group;
  • R 4 is either a link or chosen amongst a hydrogen atom, a C 1 -C 3 acyloxy group, a C 1 -C 3 alcoxy group or a phenyl group;
  • R 5 is either a link or chosen amongst a hydrogen atom, a C 1 -C 3 alcoxy group, a C 1 -C 3 acyloxy group, a C 1 -C 3 alkyl group, saturated or not, optionally substituted by a phenyl group, or a phenyl group; phenyl group being optionally substituted by one or more radicals chosen amongst: —OH, a halogen atom, a C 1 -C 3 alkyl group, a C 1 -C 3 alcoxy group, —NO 2 , —CF 3 , and
  • R 4 and R 5 can not simultaneously be a link and when R 4 or R 5 is a link then A and B are linked by a double bound
  • R 5 may also form with the adjacent hydrogen atom a cycle of 5 or 6 atoms optionally substituted by a phenyl group; optionally interrupted by a nitrogen, oxygen or sulfur atom; preferably, it is a 5-atom cycle comprising an oxygen atom;
  • R 6 represents an oxygen atom or one or two C 1 -C 3 alkyl groups
  • the invention also relates to pharmaceutically acceptable salts of compounds of general formula (II).
  • the C 1 -C 6 alkyl group means a linear or branched chain of 1 to 6 carbon atoms; such radical includes for example methyl, ethyl, propyl or isopropyl.
  • the C 1 -C 3 alkyl group means a linear or branched chain of 1 to 3 carbon atoms.
  • C 1 -C 6 alcoxy group means a —OC m H 2m+1 group, m being an integer between 1 and 6.
  • C 1 -C 3 alcoxy group means a —OC m′ H 2m′+1 group, m′ being an integer between 1 and 3.
  • C 1 -C 6 acyloxy group means a —O(CO)C n H 2n+1 or —(CO)OC n H 2n+1 group, n being an integer between 1 and 6.
  • C 1 -C 3 acyloxy group means a —O(CO)C n′ H 2n+1 or —(CO)OC n′ H 2n′+1 group, n′ being an integer between 1 and 3.
  • An aryloxy group is an aryl group linked by an oxygen atom to the rest of the compound.
  • a heteroaryloxy group is a heteroaryl linked by an oxygen atom to the rest of the compound.
  • Preferred compounds of formula (II) are such that R 3 is a link and/or R 4 is a hydrogen atom and/or R 5 is a phenyl group and/or when A is a carbon atom, then R 4 is a phenyl group and/or when B is a carbon atom then R 5 is a phenyl group.
  • derivatives benzo[e][1,4]diazepine and derivatives benzo[b][1,4]diazepine of general formula (II) are prepared as follows:
  • Compounds according to the present invention present thus an interest for the prevention and/or treatment of mammals, such as human, against disorders caused by Shiga toxins and related toxins by any route of administration.
  • the drug can be administered orally, parenterally, through the lung, ocularly, nasally . . . .
  • Compounds (I) and (II) are preferably administered nasally, through the lung, orally or parenterally.
  • the amount of compound of formula (I) or (II) administered to the mammal depends on activity of the compound, which may be measured in ways that are described in the examples. This quantity also depends on the severity of the pathology to treat, including the amount of Shiga toxin or related toxins producing bacteria absorbed; it finally depends on the age and weight of the individual to be treated.
  • FIG. 1 is a graph representing the intoxication of HeLa cells with Stxs in the absence (control) or presence of compounds 161 and 193.
  • FIG. 2 shows the results of sulfation assay as described in Example 2, part 2.
  • FIG. 3 shows pictures of cellular localisation of CtxB in comparison with the Golgi apparatus after inhibition with compounds according to the present invention.
  • FIG. 4 shows pictures of cellular localization of STxB after incubation with compound 161.
  • FIG. 5 shows pictures of cells structures after incubation with compounds 161 and 193.
  • FIG. 6 is a graph representing the degradation of EGF with or without compounds 161 or 193; EGF degradation being a tracer of lysosomal degradation.
  • FIG. 7 is a graph showing the GFP-VSVG ts045 -secretion by transfected HeLa cells in the absence and presence of compound 193, compound 161 and brefeldin A (BFA).
  • FIG. 8 is a graph showing the Shiga toxin uptake in absence (control) and presence of compound 161 or compound 193.
  • FIG. 9 is a graph showing the transferrin (Tf) uptake in absence (control) and presence of compound 161 or compound 193.
  • FIG. 10 is a graph showing the absence of effects of compounds 161 and 193 on cellular transport of endogenous cargos MPR and TGN46 (legend: (A) MPR-uptake on HeLa-MPR, (B and C) Steady-state localization of TGN46 and Cl-MPR).
  • the purification methods used for the preparation of the compounds are either filtration, Short pad (small column with silica already conditioned), column chromatography on silica gel, HPLC, crystallization or water Treatment and separation.
  • STxB-Sulf 2 , STxB-KDEL-Cy3, Cy3-STxB, Cy5-STxB, anti-TfR, mAb H68.4 and anti-STxB mAb 13C4 were prepared as previously described in Johannes and Goud, 1998 Trends Cell Biol 8(4): 158-62; Mallard et al. 1998 J Cell Biol 16;143(4):973-90).
  • anti-giantin (Abcam), anti-TfR (BD Biosciences), anti-EEA1 (Santa Cruz), anti-Lamp1 (BD Biosciences), anti-GFP (Roche), anti-TGN46 (AbD Serotech), anti-golgin-97 (Invitrogen), anti-GM130 (Santa Cruz), anti-mouse-Alexa488, anti-goat-Alexa488, anti-rabbit-Alexa488 (Molecular Probes), and anti-sheep-Cy3 (Jackson ImmunoResearch).
  • HeLa-cells were treated with 20 ⁇ M of compounds 161 or 193 before challenging them for 45 minutes at 37° C. with increasing doses of Stx1 and Stx2. Protein biosynthesis was determined 1 hour later by measuring the incorporation of radiolabeled methionine into acid-precipitable material.
  • the retrograde transport of StxB to the TGN was quantified by sulfation assay (extensively described by Amessou et al. ((2006) Curr Protoc Cell Biol Chapter 15, Unit 15 10) as early as 20 min and up to 4 h after internalization.
  • a StxB variant called StxB-Sulf 2 which bears a tandem of protein sulfation recognition sites, is internalized in the presence of 35 SO 4 2 ⁇ .
  • the TGN-localized sulfotransferase catalyzes the transfer of radioactive sulphate onto StxB-Sulf 2 .
  • [ 35 S]-sulfated StxB-Sulf 2 can be detected and quantified by autoradiography.
  • Cells were fixed with paraformaldehyde, and stained with compartment-specific antibodies such as EEA1, TfR, Vps26 (early endosomes), Rab11 (recycling endosomes), Lamp1 (late endosomes) and giantin (Golgi).
  • EEA1 EEA1
  • TfR tetrachloride
  • Vps26 early endosomes
  • Rab11 recycling endosomes
  • Lamp1 late endosomes
  • giantin Golgi
  • Cells were imaged using a Leica TCS SP2 confocal microscope with HCX PL APO-objectives (100 ⁇ /1.40-0.7 and 63 ⁇ /1.32-0.60, Leica Microsystems, Mannheim, Germany).
  • STxB Upon compounds-treatment, STxB accumulates in early endosomes, and the retrograde transport of CTxB and STxB to the TGN is markedly reduced ( FIGS. 3 and 4 ).
  • both compounds 161 and 193 were used at a final concentration of 20 ⁇ M (0.1% DMSO). Under this condition, the effect on protein biosynthesis after 2.5 h of treatment was only minor ( FIG. 1 , control versus compound-treated cells at infra-toxic toxin concentrations). The cell number was determined over 3 days of treatment and compound-treatment had no influence on cell growth.
  • 125 I-EGF was used as a tracer.
  • HeLa-cells were pre-treated with the compounds 161 and 193, prior to incubation with 125 I-EGF on ice for 30 min. After several washing steps, the cells were shifted to 37° C. in the presence of compounds. The radioactivity in TCA-insoluble and TCA-soluble fractions was quantified by scintillation after various time-points between 0-240 min.
  • VSVG vesicular stomatitis virus G protein
  • the amount of bound StxB on cells was not reduced by compound 161 or 193, as quantified by FACS.
  • HeLa-cells were compound-treated (30 min, 37° C., 20 ⁇ M), incubated on ice with STxB-Cy5 (1 ⁇ M) for 30 min, washed three times in 3% FCS/PBS, and analyzed by FACS (FACSCalibur). The fluorescence intensity corresponds to bound STxB-Cy5 on HeLa cells. 20.000 cells were analyzed for each condition. As a negative control, Gb3-depleted HeLa cells were used. For this, HeLa-cells were treated for 6 days with 5 ⁇ M of the glucosylceramide synthase inhibitor 1-phenyl-2-hexadecanoyl-amino-3-morpholino-1-propanol (PPMP).
  • PPMP glucosylceramide synthase inhibitor 1-phenyl-2-hexadecanoyl-amino-3-morpholino-1-propanol
  • StxB and transferrin The endocytosis of StxB and transferrin (Tf) was not altered after the treatment with both compounds 161 or 193.
  • cells were compound-treated (20 ⁇ M, 30 min, 37° C.), incubated on ice with StxB or Tf that are linked via a reducible disulfide bond to biotin (StxB-SS-Biotin and Tf-SS-Biotin). After washing, cells are incubated at 37° C. for different times. Biotin on surface-exposed STxB-SS-Biotin or Tf-SS-Biotin was cleaved by subsequent treatment with the non-membrane-permeable reducing agent MESNA (2-mercaptoethansulfonic acid).
  • MESNA non-membrane-permeable reducing agent
  • StxB and Tf are similarly internalized into control and compound-treated cells ( FIGS. 8 and 9 ).
  • HeLa-cells were treated for 5.5 h at 37° C. with 20 ⁇ M of compounds 193 or 161 ( FIGS. 10B and 10C ). After binding of STxB-Cy3 on ice, cells were incubated for another 45 min at 37° C. in the presence of compounds 193 or 161, fixed and stained for the indicated antibodies. Note that the steady-state localization of CI-MPR and TGN46 is similar under control and compound-treatment conditions. These results suggest, that both compounds have no effect on the transport of both proteins, and thus on their steady-state localization.
  • THP1-cells were used to characterize the inhibitory effect of the compounds. Concentrations of up to 100 ⁇ M of compounds did not cause any reduction in the overall protein biosynthesis.
  • THP1-cells were incubated with 100 ⁇ M of compound for 30 min at 37° C., before binding of StxB on ice for 30 min and internalization for 45 mn at 37° C. Fixed cells were stained for the Golgi-marker giantin.
  • Stxs after treatment with compounds 161 or 193 of toxin-sensitive HeLa-cells, a 50-100 ⁇ higher dose of toxin is necessary to cause a similar inhibitory effect on protein-biosynthesis as on control cells.
  • This effect is attributed to an inhibition in the retrograde transport of the toxin at the interface between early endosomes and Golgi apparatus, and it is not due to a reduction in toxin binding or internalization, or an unspecific effect on cellular morphology or functional alteration of cellular compartments.
  • the transport of StxB to the trans-Golgi network was reduced by 60-90%, as verified by sulfation assay.
  • compounds 161 and 193 are specific to exogenous toxins (Shiga and cholera toxins) and they unexpectedly do not impact distinctly the transport of endogenous cargo (CI-M6PR, TGN46). Additionally, these compounds do no have any effect on the morphology of cellular compartments and do not influence cellular growth even after longer treatments (several days). Also, their effect is restricted to the retrograde transport route and does not influence anterograde transport, degradation or endocytosis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.

Description

  • The invention relates to the use of imine and benzodiazepine derivatives as therapeutic agents, particularly in the treatment of disorders caused by Shiga toxins.
  • Shigella dysenteriae, some strains of Escherichia coli as well as other bacteria can secrete Shiga toxins (Stxs), which cause serious complications and deaths during infections.
  • There are multiple sources of Shiga toxin producing pathogens involved in sporadic cases and outbreaks of disease. Shiga toxin producing bacteria are associated with a broad spectrum of clinical manifestations in humans ranging from asymptomatic colonization to life threatening hemolytic uremic syndrome (HUS) (Tarr et al. (2005). Lancet 365, 1073-1086).
  • In North America, most cases and outbreaks of infection by these pathogens have been associated with Shiga toxin-producing Escherichia coli (STEC) and more specifically the single E. coli serotype O157:H7. These endemic or epidemic cases begin through the ingestion of STEC. Although STEC infection may be asymptomatic, it typically begins with an onset of watery diarrhea between 2 and 12 days after STEC ingestion and is frequently associated with abdominal pain and occasionally with nausea and vomiting (Tarr et al., 2005). Watery diarrhea lasts for 1-3 days after which, in 90% of the cases, it progresses to bloody diarrhea (Tarr at al., 2005). Then approximately 15% of the STEC-infected subjects develop HUS.
  • The course of the disease between bloody or non-bloody diarrhea and HUS is not well characterized but the HUS is defined as microangiopathic hemolytic anemia (with fragmented red blood cells: schistocytes), thrombocytopenia and nephropathy. Other extra-renal complications of HUS may also subsequently occur such as seizures, intracranial infarction or hemorrhage, retinal hemorrhage and encephalopathy, acute pancreatitis, cardiomyopathy and death (in ˜4%) (Elliott, E. J., and Robins-Browne, R. M. (2005). Curr Probl Pediatr Adolesc Health Care 35, 310-330). Even though approximately half of STEC infections do not require medical care, a small percentage of cases develop HUS with after-effects such as chronic kidney failure requiring lifelong dialysis or a kidney transplant.
  • Centers for Disease Control and Prevention (CDC) provides epidemiological figures of the number of incident STEC infections (Mead et al., (1999) Emerg Infect Dis 5, 607-625). Authors evaluated the total number of STEC infections annually to be 110,220 in USA.
  • Shiga toxins belong to the toxins that use the cell retrograde transport; these toxins include ricin (produced in the seeds of the castor oil plant Ricinus communis), Shiga and Shiga-like toxins (Stx1 and Stx2, together designated Stxs, produced by Shigella dysenteriae and E. coli), cholera toxin (Ctx produced by Vibrio cholerae), heat-labile enterotoxin (produced by E. coli), pertussis toxin (produced by Bordetella pertussis), and subtilase cytotoxin (produced by E. coli). These toxins share a similar structural organization: a receptor-binding B-subunit associated with a catalytic active A-subunit.
  • After binding to their target cell receptors, these toxins are internalized and transported to early endosomes (EE). Instead of being recycled back to the plasma membrane or transported to late endosomes/lysosomes for degradation, an important number of toxin molecules gain access to the Golgi apparatus and the endoplasmic reticulum (ER), from where their A-subunits are retro-translocated into the cytosol (Sandvig et al. (2002) Annu. Rev. Cell Dev. Biol. 18:1-24). Then, the A-subunits of Stxs toxins and ricin remove a conserved adenine-residue from ribosomal RNA, leading to an inhibition of protein biosynthesis and apoptosis, whereas the A-subunit of cholera toxin modifies the stimulatory G-protein Gsα, causing the untamed, constitutive production of the secondary messenger cAMP, which finally provokes a dramatic efflux of ions and water from the digestive track.
  • The unique intracellular transport pathway of these toxins from the early endosomes to the ER via the Golgi apparatus (retrograde transport) offers the opportunity to search for pharmacologically active compounds capable of blocking this pathway. Small molecules that inhibit the retrograde transport of these toxins would prevent their delivery into the cytosol, where they exert their deadly effect.
  • To date, there is no proven safe treatment for STEC infections and prevention of Shiga toxin-mediated complications other than supportive care. Moreover, the use of antibiotics seems to exacerbate the disease. Considering that Shiga toxin is the major virulence factor secreted by STEC and that Stxs plays a pivotal role in the pathogenesis of HUS, most treatment strategies aim at neutralizing Stxs.
  • Development of compounds capable of inhibiting the cellular toxin binding targeting the B-subunit of the toxin has been studied leading to a synthetic analog of Shiga toxin receptor, this analog is composed of silicon dioxide particles covalently linked to the trisaccharide moiety (globotriose [α-D-Gal-(1→4)-β-D-Gal-(1→4)-D-Glc]) of the globotriaosylceramide molecule that mediates Shiga toxin binding; it was the first compound that was tested in humans (Synsorb Pk, see Armstrong et al., 1995). Synsorb Pk was designed to trap and eliminate free Stxs produced in the gut of patients infected by Stx-producing E. coli, and to prevent the progression of hemorrhagic colitis to hemolytic uremic syndrome. However, this Shiga toxin-binding agent failed to diminish the severity of disease in pediatric patients with diarrhea-associated HUS (Trachtman et al., (2003) Jama 290, 1337-1344).
  • Since then, other molecules with improved affinity towards the B-subunit of Stxs (StxB) have been developed:
  • a water-soluble carbohydrate ligand of Stxs, analog to its carbohydrate receptor (Starfish, see Kitov et al. (2000) Nature 403, 669-672):
  • Figure US20110201601A1-20110818-C00001
  • Structure of the Water Soluble Ligand of Stxs, Starfish
  • a carbosilane dendrimer carrying various numbers of trisaccharides which is the first synthetic Stx2 inhibitor to function in vivo (Super Twig, Nishikawa et al. (2002) Proc Natl Acad Sci USA 99, 7669-7674). However, the clinical application of these carbosilane dendrimers has been substantially hampered by the synthetic complexity of its trisaccharide moiety.
  • Figure US20110201601A1-20110818-C00002
  • Structure of the Synthetic Stx2 Inhibitor, Super Twig
  • others Stx inhibitors, containing trisaccharides, have also been described for their ability to protect animals.
  • Another approach aims at inactivating the catalytic active A-subunit of the toxin (StxA).
  • Several purine derivatives have been assayed as inhibitors of Stx RNA-N-glycosidase activity. 4-aminopyrazolo[3,4-d]pyrimidine (4-APP) is by far the most potent inhibitor of enzymatic reactions catalyzed by Stx1. However, experiments were realized in acellular in vitro assay and the IC50 of Stx1 was shifted by one order of magnitude in presence of 0.8 mM 4-APP. Thus, it appears that therapeutic potential of such compounds is low.
  • Another strategy intends to act directly on cellular processes hijacked by Stxs and not on the toxin itself. In the past, it has been shown for a limited number of small molecules that they are able to inhibit the retrograde transport of certain toxins (Ricin, Shiga and cholera toxins), Exo2 (Spooner et al. (2008) Biochem J 414, 471-484), Brefeldin A (Donta et al., 1995), Golgicide and others (Saenz et al. (2007) Infect Immun 75, 4552-4561; Saenz et al. (2009) Nat Chem Biol 5, 157-165).
  • Yet, these compounds are rather unspecific, as they affect the morphology of cellular compartments. Their effect is thus not restricted to the retrograde transport pathway (the anterograde/biosynthetic transport is affected, too) or to these toxins (the transport of endogenous proteins is affected as well). Treatment is most likely not possible without causing severe side effects.
  • There is thus a need for the development of compounds intended for safe treatment for infections and prevention of Shiga toxin-mediated complications other than supportive care.
  • The inventors have found that unexpectedly the compounds of formula (I) (imine derivatives) and the compounds of formula (II) (benzodiazepine derivatives) are efficient for preventing and/or treating Shiga toxins cells intoxications.
  • The present invention relates to the use of an imine derivative of formula (I):
  • Figure US20110201601A1-20110818-C00003
  • wherein:
  • X is —NH— or —O—;
  • R1 is a cycloalkyl radical having 5 to 10 carbon atoms, having one or two rings, saturated or not, wherein one or more carbon atom may be replaced by a nitrogen, oxygen or sulfur atoms; said cycloalkyl radical being optionally substituted by one or more groups chosen amongst a halogen atom, a hydroxyl function, a nitro function and a C1-C3 alkyl group,
  • R2 is a hydrogen atom or a link; when R2 is a link, then the nitrogen atom forms a double bond with the adjacent carbon atom;
  • for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.
  • Shiga toxins and related toxins include the Shiga toxin (Stx) produced by Shigella dysenteriae, Shiga-like toxin 1 and 2 (SLT-1 and 2 or Stx-1 and 2 or Verotoxin 1 and 2) produced by Shigatoxigenic group of Escherichia coli (STEC), which includes serotype O157:H7 and other enterohemorrhagic E. coli and cholera toxin (Ctx).
  • Disorders caused by Shiga toxins and related toxins include abdominal pain, nausea, vomiting, diarrhea, watery diarrhea, bloody diarrhea, hemolytic uremic syndrome (HUS): microangiocytopenia anemia, thrombocytopenia and nephropathy and other extra-renal complication of HUS: seizure, intracranial infarction or hemorrhage, retinal hemorrhage and encephalopathy, acute pancreatitis and cardiomyopathy.
  • The present invention also relates to pharmaceutically acceptable salt of compounds of formula (I) such as hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen, acetate, oxalate, benzoate, succinate, fumarate, maleate, lactate, citrates, tartrate, gluconate, methanesulphonate, benzene-sulphonate and paratoluene-sulphonate.
  • By halogen atom is meant the chemical elements of group VII of the periodic table of elements; including fluorine, chlorine, bromine and iodine. The preferred halogen is bromine (Br) and fluorine (F).
  • The term C1-C3 alkyl group means a linear or branched chain of 1 to 3 carbon atoms; said chain may be for example methyl, ethyl, propyl or isopropyl.
  • Compounds of general formula (I) may be chosen from:
  •
    149 2-(3-bromobenzylideneamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00004
    150 2-(3-bromobenzylamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00005
    151 2-(3-fluorobenzylideneamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00006
    152 (E)-2-((furan-2-yl)methyleneamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00007
    153 (E)-2-((furan-3-yl)methyleneamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00008
    154 (E)-2-((5-methylfuran-2- yl)methyleneamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00009
    155 (E)-2-(5-fluoro-2- nitrobenzylideneamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00010
    156 (E)-2-(4-fluorobenzylideneamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00011
    157 (E)-2-(2-fluorobenzylideneamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00012
    158 (E)-2-((1-methyl-1H-indol-2- yl)methyleneamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00013
    159 (E)-2-(5-bromo-2- hydroxybenzylideneamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00014
    160 2-(2-fluorobenzylamino)-N- phenylbenzamide
    Figure US20110201601A1-20110818-C00015
    161 (E)-2-(2-(5-methylthiophen-2-yl)vinyl)- N-phenylbenzamide
    Figure US20110201601A1-20110818-C00016
  • The preparation of said imine derivatives is achieved by adding a solution of an amine in methanol to an aldehyde, said amine and aldehyde being chosen according to the imine derivative to prepare, and the mixture is stirred for 2 days. The imine derivatives are obtained after evaporation and purification.
  • The evaporation is performed as follows: a solution of imine in methanol is added on BH3CN resin (3 equiv.) and AcOH. After 3 days at room temperature (15-25° C.), the mixture is filtered, washed with methanol and then concentrated under vacuum. The crude compound thus obtained is purified by conventional methods.
  • The present invention also relates to the use of a benzodiazepine derivative of formula (II):
  • Figure US20110201601A1-20110818-C00017
  • wherein
  • A and B are a carbon atom or a nitrogen atom with the proviso that when A=N then B═C and when A=C then B═N;
  • R3 is chosen amongst a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a C1-C6 alcoxy group, a C1-C6 acyloxy group, an aryloxy group, a heteroaryloxy group; these groups being optionally substituted by a C1-C6 alcoxy group or a heteroaryloxy group;
  • R4 is either a link or chosen amongst a hydrogen atom, a C1-C3 acyloxy group, a C1-C3 alcoxy group or a phenyl group;
  • R5 is either a link or chosen amongst a hydrogen atom, a C1-C3 alcoxy group, a C1-C3 acyloxy group, a C1-C3 alkyl group, saturated or not, optionally substituted by a phenyl group, or a phenyl group; phenyl group being optionally substituted by one or more radicals chosen amongst: —OH, a halogen atom, a C1-C3 alkyl group, a C1-C3 alcoxy group, —NO2, —CF3, and
  • Figure US20110201601A1-20110818-C00018
  • with the proviso that R4 and R5 can not simultaneously be a link and when R4 or R5 is a link then A and B are linked by a double bound,
  • R5 may also form with the adjacent hydrogen atom a cycle of 5 or 6 atoms optionally substituted by a phenyl group; optionally interrupted by a nitrogen, oxygen or sulfur atom; preferably, it is a 5-atom cycle comprising an oxygen atom;
  • R6 represents an oxygen atom or one or two C1-C3 alkyl groups;
  • for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.
  • The invention also relates to pharmaceutically acceptable salts of compounds of general formula (II).
  • The C1-C6 alkyl group means a linear or branched chain of 1 to 6 carbon atoms; such radical includes for example methyl, ethyl, propyl or isopropyl. The C1-C3 alkyl group means a linear or branched chain of 1 to 3 carbon atoms.
  • C1-C6 alcoxy group means a —OCmH2m+1 group, m being an integer between 1 and 6.
  • C1-C3 alcoxy group means a —OCm′H2m′+1 group, m′ being an integer between 1 and 3.
  • C1-C6 acyloxy group means a —O(CO)CnH2n+1 or —(CO)OCnH2n+1 group, n being an integer between 1 and 6.
  • C1-C3 acyloxy group means a —O(CO)Cn′H2n+1 or —(CO)OCn′H2n′+1 group, n′ being an integer between 1 and 3.
  • An aryloxy group is an aryl group linked by an oxygen atom to the rest of the compound.
  • A heteroaryloxy group is a heteroaryl linked by an oxygen atom to the rest of the compound.
  • Preferred compounds of formula (II) are such that R3 is a link and/or R4 is a hydrogen atom and/or R5 is a phenyl group and/or when A is a carbon atom, then R4 is a phenyl group and/or when B is a carbon atom then R5 is a phenyl group.
  • Compounds of general formula (II) may be chosen from:
  •
    162 5-phenyl-2,3-dihydro-1H-1,4- benzodiazepin-2-one
    Figure US20110201601A1-20110818-C00019
    163 7-bromo-5-phenyl-2,3-dihydro-1H-1,4- benzodiazepin-2-one
    Figure US20110201601A1-20110818-C00020
    164 7-bromo-5-phenyl-2,3,4,5-tetrahydro-1H- 1,4 -benzodiazepin-2-one
    Figure US20110201601A1-20110818-C00021
    165 4-phenyl-2,3-dihydro-1H-1,5- benzodiazepin-2-one
    Figure US20110201601A1-20110818-C00022
    166 4-phenyl-2,3,4,5-tetrahydro-1H-1,5- benzodiazepin-2-one
    Figure US20110201601A1-20110818-C00023
    167 4,5-dihydro-7-methoxy-5-phenyl-1H- benzo[e][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00024
    168 Ethyl 4-oxo-2-phenyl-2,3,4,5-tetrahydro- 1H-1,5-benzodiazepine-1-carboxylate
    Figure US20110201601A1-20110818-C00025
    169 5-phenyl-2,3,4,5-tetrahydro-1H-1,4- benzodiazepin-2-one
    Figure US20110201601A1-20110818-C00026
    170 7-chloro-5-phenyl-2,3-dihydro-1H-1,4- benzodiazepin-2-one
    Figure US20110201601A1-20110818-C00027
    171 7-chloro-5-phenyl-2,3,4,5-tetrahydro-1H- 1,4-benzodiazepin-2-one
    Figure US20110201601A1-20110818-C00028
    172 4-(2-hydroxyphenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00029
    173 4-(5-bromo-2-hydroxyphenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00030
    174 4-(5-fluoro-2-hydroxyphenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00031
    175 8-bromo-3-phenyl-3,3a,5,10- tetrahydrobenzo[b]pyrrolo[2,3- e][1,4]diazepin-4(2H)-one
    Figure US20110201601A1-20110818-C00032
    176 4-m-tolyl-1H-benzo[b][1,4]diazepin-2(3H)- one
    Figure US20110201601A1-20110818-C00033
    177 4-(3-methoxyphenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00034
    178 4-(3-nitrophenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00035
    179 4-(3-chlorophenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00036
    180 4-(3-bromophenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00037
    181 4-(3-(trifluoromethyl)phenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00038
    182 7-bromo-4-m-tolyl-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00039
    183 7-bromo-4-(3-methoxyphenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00040
    184 7-bromo-4-(3-nitrophenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00041
    185 7-bromo-4-(3-chlorophenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00042
    186 7-bromo-4-(3-bromophenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00043
    187 7-bromo-4-(3-(trifluoromethyl)phenyl)-1H- benzo[b][1,4]diazepin-2(3H)-one
    Figure US20110201601A1-20110818-C00044
    188 7-bromo-2,2,4-trimethyl-2,3-dihydro-1H- benzo[b][1,4]diazepine
    Figure US20110201601A1-20110818-C00045
    189 (E)-7-bromo-2,2-dimethyl-4-styryl-2,3- dihydro-1H-benzo[b][1,4]diazepine
    Figure US20110201601A1-20110818-C00046
    190 (E)-7-bromo-4-(3-bromostyryl)-2,2- dimethyl-2,3-dihydro-1H- benzo[b][1,4]diazepine
    Figure US20110201601A1-20110818-C00047
    193 7-bromo-5-phenyl-4-propionyl-4,5- dihydro-1H-benzo[e][1,4]diazepin-2(3H)- one
    Figure US20110201601A1-20110818-C00048
  • The synthesis of compounds of general formula (II) according to the invention is described in example 1.
  • In particular, derivatives benzo[e][1,4]diazepine and derivatives benzo[b][1,4]diazepine of general formula (II) are prepared as follows:
  • adding to a suspension of diamine, chosen according to the compound of general formula (II) to be prepared, for example, benzene-1,2-diamine or 4-bromobenzene-1,2-diamine (1 equiv.), a β-ketoester (1 equiv.) in toluene (2 ml);
  • stirring the mixture to reflux (120° C.) for 3 hours;
  • diluting the mixture in ethyl acetate, acidification (pH 5) and extraction with ethyl acetate;
  • filtering, evaporating and washing with diethyl ether.
  • Inventors have demonstrated that compounds of the invention, in particular, compounds 161 and 193 (see Example 2), are able to block specifically the retrograde route used by bacterial toxins (Shiga and Cholera toxins) and potently block Stx cytotoxicity (100-fold inhibition).
  • Compounds according to the present invention present thus an interest for the prevention and/or treatment of mammals, such as human, against disorders caused by Shiga toxins and related toxins by any route of administration.
  • The skilled person will adapt the formulation of compounds of general formula (I) and (II) according to their physicochemical properties and their route of administration.
  • The drug can be administered orally, parenterally, through the lung, ocularly, nasally . . . . Compounds (I) and (II) are preferably administered nasally, through the lung, orally or parenterally.
  • The amount of compound of formula (I) or (II) administered to the mammal depends on activity of the compound, which may be measured in ways that are described in the examples. This quantity also depends on the severity of the pathology to treat, including the amount of Shiga toxin or related toxins producing bacteria absorbed; it finally depends on the age and weight of the individual to be treated.
  • The use of compounds of general formula (I) or (II) is particularly advantageous for treating disorders caused by Shiga toxins and related toxins using the route of internalization to infect the cell.
  • In addition to the above provisions, the invention also comprises other provisions which will become clear from the description which follows, which refers to examples illustrating the biological activity of compounds of general formula (I) and (II), and also to the attached drawings in which:
  • FIG. 1 is a graph representing the intoxication of HeLa cells with Stxs in the absence (control) or presence of compounds 161 and 193.
  • FIG. 2 shows the results of sulfation assay as described in Example 2, part 2.
  • FIG. 3 shows pictures of cellular localisation of CtxB in comparison with the Golgi apparatus after inhibition with compounds according to the present invention.
  • FIG. 4 shows pictures of cellular localization of STxB after incubation with compound 161.
  • FIG. 5 shows pictures of cells structures after incubation with compounds 161 and 193.
  • FIG. 6 is a graph representing the degradation of EGF with or without compounds 161 or 193; EGF degradation being a tracer of lysosomal degradation.
  • FIG. 7 is a graph showing the GFP-VSVGts045-secretion by transfected HeLa cells in the absence and presence of compound 193, compound 161 and brefeldin A (BFA).
  • FIG. 8 is a graph showing the Shiga toxin uptake in absence (control) and presence of compound 161 or compound 193.
  • FIG. 9 is a graph showing the transferrin (Tf) uptake in absence (control) and presence of compound 161 or compound 193.
  • FIG. 10 is a graph showing the absence of effects of compounds 161 and 193 on cellular transport of endogenous cargos MPR and TGN46 (legend: (A) MPR-uptake on HeLa-MPR, (B and C) Steady-state localization of TGN46 and Cl-MPR).
    •  EXAMPLE 1 Synthesis of Compounds According to the Invention
  • Commercial reagents were purchased from Sigma-Aldrich and were used without prior purification. All reactions were performed under nitrogen with freshly distilled dry solvents and glassware dried in an oven.
  • The purification methods used for the preparation of the compounds are either filtration, Short pad (small column with silica already conditioned), column chromatography on silica gel, HPLC, crystallization or water Treatment and separation.
  • 1H NMR was performed with a Brucker Advance 400 MHz with a BBO probe. Solvents are specified for each experiment. The chemical displacements are given in parts per million (ppm), compared to the internal reference (TMS). The data are listed in the following order: δ, chemical shift, multiplicity (s: singlet, d: doublet, t: triplet, q: quadruplet, m: multiplet), integration, coupling constants (J in Hertz, Hz).
  • Analysis of LC/MS were performed by HPLC (High Pressure Liquid Chromatography) coupled with a mass spectrometer WATERS® AUTOPURIF. Ionization is obtained by electronical collision or by electrochemical ionization. The data are obtained as m/z.
    • Column: Xbridge C18 3-5 μM, 4.6 mm*100 mm
    • Flow rate: 1.0 mL/min
    • Detectors:
    • Photodiode array detector Waters 2996: UV (200-400 nm),
    • PL-ELS 1000,
    • MS ZQ 2000.
    • Injection volume: 1 uL with Autosampler Waters 2767
    • Method: 95% solution A (99.99% water, 0.01% formic acid), 5% B (100% acetonitrile) to 0% A, B on 100% gradient of 8 minutes and 5 minutes of landing.
      The column chromatographies were carried out with silica gel Merck (particle size: 230-400 mesh). All reactions were monitored by thin layer chromatography plates with preenduites silica gel 0.2 mm thick 60G-264 (Merck). The revelation was performed with a UV lamp or iodine.
  • Imine Derivatives
  • Amination
  • To a solution of nitroacid (8 g; 47.9 mmol; 1 equiv.) in CH2Cl2 (100 mL) were added DCC (10.9 g; 52.7 mmol; 1.1 equiv.), DMAP (1.17 g, 9.6 mmol, 0.2 equiv.) and aniline (6.1 mL; 67.1 mmol; 1.4 equiv.) at room temperature. The mixture was stirred 4 days and evaporated. The solid was taken in aceton and was filtered.
  • The brown filtrate was evaporated to give a brown solid which was washed with Et2O to give 2-nitro-N-phenylbenzamide as an orange solid (11.6 g; 71%).
  • To a solution of 2-nitro-N-phenylbenzamide (5 g; 20.7 mmol; 1 equiv.) in MeOH (65 mL) was added palladium on charcoal (550 mg) and decaborane (757 mg; 6.2 mmol; 0.3 equiv.) at room temperature. The mixture was heated at 60° C. for 6 hours, filtered over celite, washed with AcOEt and evaporated to give 2-amino-N-phenylbenzamide as brown solid (4.2 g; 96%) which was used without further purification.
  • To a solution of 2-amino-N-phenylbenzamide (42 mg; 0.2 mmol; 1 equiv.) in MeOH (2 mL) was added aldehyde (0.2 mmol; 1 equiv.) and the mixture was stirred 2 days at room temperature, evaporated and purified by appropriate method if necessary.
  • This process allows the synthesis of the following compounds:
  • Figure US20110201601A1-20110818-C00049
    • Preparation of (E)-2-((furan-2-yl)methyleneamino)-N-phenylbenzamide (compound 152)
  • Figure US20110201601A1-20110818-C00050
  • From furan-2-carbaldehyde, a yellow solid (99%) is obtained
  • 1H NMR (CDCl3, 400 MHz): δ 8.02 (dd, 1H, J=1.2 and 8 Hz), 7.40-7.24 (m, 7H), 6.91 (t, 1H, J=8 Hz), 6.70 (d, 1H, J=8 Hz), 6.33 (d, 1H, J=3.2 Hz), 6.25 (dd, 1H, J=2 and 3.2 Hz), 6.06 (d, 1H, J=2 Hz), 4.94 (bs, 1H).
  • 13C NMR (CDCl3, 100 MHz): δ 162.6, 152.2, 145.1, 142.6, 140.6, 133.7, 128.9, 128.8, 126.7, 126.1, 119.7, 117.1, 115.1, 110.3, 109.0, 68.4.
  • ESI+MS: calcd for C18H14N2O2: 290.11; found: 291.1 (MH+)
    • Preparation of (E)-2-((5-methylfuran-2-yl)methyleneamino)-N-phenylbenzamide (compound 154)
  • Figure US20110201601A1-20110818-C00051
  • From 5-methylfuran-2-carbaldehyde, a yellow solid (100%) is obtained. ESI+MS: calcd for C19H16N2O2: 304.12; found: 305.0 (MH+)
    • Preparation of (E)-2-((furan-3-yl)methyleneamino)-N-phenylbenzamide (compound 153)
  • Figure US20110201601A1-20110818-C00052
  • From furan-3-carbaldehyde, a yellow solid (97%) is obtained.
  • 1H NMR (CDCl3, 400 MHz): δ 8.02 (d, 1H, J=7.6 Hz), 7.39-7.23 (m, 7H), 6.93 (t, 1H, J=7.6 Hz), 6.70 (d, 1H, J=8 Hz), 6.28 (s, 1H), 6.04 (s, 1H), 4.70 (bs, 1H).
  • 13C NMR (CDCl3, 100 MHz): δ 162.7, 145.5, 143.6, 140.8, 140.4, 133.8, 129.0, 128.9, 126.9, 126.7, 125.5, 119.7, 117.1, 115.2, 108.7, 67.7.
  • ESI+MS: calcd for C18H14N2O2: 290.11; found: 291.1 (MH+)
    • Preparation of (E)-2-(2-fluorobenzylideneamino)-N-phenylbenzamide (compound 157)
  • Figure US20110201601A1-20110818-C00053
  • From 2-fluorobenzaldehyde, a yellow solid (53%) is obtained. ESI+MS: calcd for C20H15FN2O: 318.12; found: 319.1 (MH+)
    • Preparation of (E)-2-(3-fluorobenzylideneamino)-N-phenylbenzamide (compound 151)
  • Figure US20110201601A1-20110818-C00054
  • From 3-fluorobenzaldehyde, this product is obtained with a yield=100% ESI+MS: calcd for C20H15FN2O: 318.12; found: 319.1 (MH+)
    • Preparation of (E)-2-(3-bromobenzylideneamino)-N-phenylbenzamide (compound 149)
  • Figure US20110201601A1-20110818-C00055
  • From 3-bromobenzaldehyde, this product is obtained with a yield=100%
  • 1H NMR (DMSO-d6, 400 MHz): δ 8.40 (s, 1H), 7.70-6.60 (m, 13H, H).
    • Preparation of (E)-2-(4-fluorobenzylideneamino)-N-phenylbenzamide (compound 156)
  • Figure US20110201601A1-20110818-C00056
  • From 4-fluorobenzaldehyde, a yellow oil (8%) is obtained.
  • 1H NMR (DMSO d6, 400 MHz): δ 9.43 (s, 1H), 7.62-6.72 (m, 13H)
  • ESI+MS: calcd for C20H15BrN2O: 318.12; found: 319.2 (MH+)
    • Preparation of (E)-2-(5-fluoro-2-nitrobenzylideneamino)-N-phenylbenzamide (compound 155)
  • Figure US20110201601A1-20110818-C00057
  • From 5-fluoro-2-nitrobenzaldehyde, a yellow oil (2.9%) is obtained.
  • ESI+MS: calcd for C20H14FN3O3: 363.34; found: 364.1 (MH+)
    • Preparation of (E)-2-(5-bromo-2-hydroxybenzylideneamino)-N-phenylbenzamide (compound 159)
  • Figure US20110201601A1-20110818-C00058
  • From 5-bromo-2-hydroxybenzaldehyde, a yellow oil (92%) is obtained.
  • ESI+MS: calcd for C20H15BrN2O2: 394.03; found: 395.0 (MH+)
    • Preparation of (E)-2-((1-methyl-1H-indol-2-yl)methyleneamino)-N-phenylbenzamide (compound 158)
  • Figure US20110201601A1-20110818-C00059
  • From 1-methyl-1H-indole-2-carbaldehyde, a yellow oil (12%) is obtained.
  • ESI+MS: calcd for C23H19N3O: 353.15; found: 354.2 (MH+)
  • Reductive Amination
  • Figure US20110201601A1-20110818-C00060
    • Preparation of 2-(3-bromobenzylamino)-N-phenyl benzamide (compound 150)
  • Figure US20110201601A1-20110818-C00061
  • From (E)-2-(3-bromobenzylideneamino)-N-phenylbenzamide Yield=100%
    • Preparation of 2-(2-fluorobenzylamino)-N-phenylbenzamide (compound 160)
  • Figure US20110201601A1-20110818-C00062
  • From (E)-2-(2-fluorobenzylideneamino)-N-phenylbenzamide, colourless oil (1%) is obtained.
  • ESI+MS: calcd for C20H17FN2O: 320.13; found: 321.0 (MH+)
  • Benzodiazepines
  • Synthesis of benzo[e][1,4]diazepin
  • Figure US20110201601A1-20110818-C00063
    • Preparation of (Z)-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (compound 162)
  • Figure US20110201601A1-20110818-C00064
  • From (2-aminophenyl)(phenyl)methanone, the compound is obtained with a yield=53%.
  • 1H NMR (CDCl3, 400 MHz): δ 48.45 (s, 1H), 7.64-7.26 (m, 9H), 4.34 (s, 2H).
  • ESI+MS: calcd for C15H12N2O: 236.09; found: 237 (MH+)
    • Preparation of (Z)-7-chloro-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (compound 170)
  • Figure US20110201601A1-20110818-C00065
  • From (2-amino-5-chlorophenyl)(phenyl)methanone, the compound is obtained with a yield=17%.
  • 1H NMR (CDCl3, 400 MHz,): δ 9.42 (s, 1H), 7.78-7.16 (m, 8H), 4.33 (s, 2H).
  • ESI+MS: calcd for C15H11ClN2O: 270.06; found: 271 (MH+)
    • Preparation of (Z)-7-bromo-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (compound 163)
  • Figure US20110201601A1-20110818-C00066
  • From (2-amino-5-bromophenyl)(phenyl)methanone, the compound is obtained with a yield=26%
  • 1H NMR (CDCl3, 400 MHz): δ 9.26 (s, 1H), 7.90-7.32 (m, 8H), 4.37 (s, 2H).
  • ESI+MS: calcd for C15H11BrN2O: 314.01; found: 315 (MH+)
    • Synthesis of benzo[b][1,4]diazepin
  • Figure US20110201601A1-20110818-C00067
  • To a stirred suspension of diamine (0.5 mmol; 54 mg; 1 equiv.) in toluene (2 mL) was added β-ketoester (0.5 mmol; 1 equiv.). The mixture was stirred at reflux (120° C.) during 3 hours. The mixture was diluted with EtOAc, acidified (pH 5), extracted with EtOAc, filtered, evaporated and washed with Et2O to give the expected compound.
    • From benzene-1,2-diamine Preparation of (E)-4-phenyl-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 165)
  • Figure US20110201601A1-20110818-C00068
  • From ethyl 3-oxo-3-phenylpropanoate, a colorless oil (69%) is obtained
  • 1H NMR (CDCl3, 400 MHz): δ 12.88 (s, 1H), 8.17-6.64 (m, 9H), 5.50 (s, 2H).
  • ESI+MS: calcd for C15H12N2O: 236.09; found: 237 (MH+)
    • Preparation of (E)-4-m-tolyl-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 176)
  • From ethyl 3-oxo-3-m-tolylpropanoate, a brown solid (31%) is obtained
  • 1H NMR (CDCl3, 400 MHz): δ 7.94 (s, 1H), 7.91 (d, 1H, J=8 Hz), 7.69 (bs, 1H), 7.54 (d, 1H, J=8.8 Hz), 7.38 (t, 1H, J=7.6 Hz), 7.31 (m, 2H), 7.05 (dd, 1H, J=1.6 and 7.6 Hz), 3.59 (s, 2H), 2.45 (s, 3H).
  • ESI+MS: calcd for C16H14N2O: 250.11; found: 250.1 (MH+)
    • Preparation of (E)-4-(3-methoxyphenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 177)
  • From ethyl 3-(3-methoxyphenyl)-3-oxopropanoate, brown solid (20%) is obtained.
  • 1H NMR (CDCl3, 400 MHz): δ 7.68 (m, 3H), 7.55 (dd, 1H, J=2 and 8 Hz), 7.40 (t, 1H, J=8.4 Hz), 7.28 (m, 1H), 7.06 (dt, 2H, J=2.8 and 8 Hz), 3.91 (s, 3H), 3.58 (s, 2H).
  • 13C NMR (CDCl3, 100 MHz): δ 167.3, 159.9, 158.8, 139.8, 138.9, 129.7, 128.9, 128.3, 126.5, 125.2, 121.6, 120.4, 117.7, 112.2, 55.5, 39.9.
  • ESI+MS: calcd for C16H14N2O2: 266.11; found: 267.0 (MH+)
    • Preparation of (E)-4-(3-nitrophenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 178)
  • From ethyl 3-(3-nitrophenyl)-3-oxopropanoate, a brown solid (23%) is obtained.
  • 1H NMR (CDCl3, 400 MHz): δ 9.00 (t, 1H, J=2 Hz), 8.40 (d, 1H, J=8 Hz), 8.35 (dd, 1H, J=1.6 and 8 Hz), 7.73 (bs, 1H), 7.68 (t, 1H, J=8.4 Hz), 7.55 (m, 1H), 7.32 (m, 2H), 7.09 (m, 1H), 3.62 (s, 2H).
  • ESI+MS: calcd for C15H11N3O3: 281.08; found: 282.0 (MH+)
    • Preparation of (E)-4-(3-chlorophenyI)-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 179)
  • From ethyl 3-(3-chlorophenyI)-3-oxopropanoate, a brown solid (15%) is obtained.
  • 1H NMR (CDCl3, 400 MHz): δ 8.14 (t, 1H, J=1.6 Hz), 7.96 (d, 1H, J=7.6 Hz), 7.76 (bs, 1H), 7.53-7.41 (m, 3H), 7.29 (m, 2H), 7.07 (dd, 1H, J=1.2 and 6.8 Hz), 3.56 (s, 2H).
  • 13C NMR (CDCl3, 100 MHz): δ 167.1, 157.3, 139.7, 139.3, 135.0, 131.0, 129.9, 128.9, 128.4, 127.8, 126.9, 125.8, 125.3, 121.7, 39.7.
    • Preparation of (E)-4-(3-bromophenyI)-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 180)
  • From ethyl 3-(3-bromophenyl)-3-oxopropanoate, a brown solid (7%) is obtained.
  • 1H NMR (CDCl3, 400 MHz): δ 8.30 (t, 1H, J=1.6 Hz), 8.00 (d, 1H, J=8 Hz), 7.77 (bs, 1H), 7.63 (dd, 1H, J=0.8 and 8 Hz), 7.52 (dd, 1H, J=2 and 7.6 Hz), 7.36 (t, 1H, J=8 Hz), 7.27 (m, 1H), 7.07 (dd, 1H, J=1.6 and 7.2 Hz), 3.55 (s, 2H).
  • 13C NMR (CDCl3, 100 MHz): δ 166.9, 157.3, 139.7, 139.3, 133.9, 130.7, 130.2, 128.8, 128.4, 126.9, 126.3, 125.3, 123.1, 121.7, 39.7.
    • Preparation of (E)-4-(3-(trifluoromethyl)phenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 181)
  • From ethyl 3-(3-(trifluoromethyl)phenyl)-3-oxopropanoate, a brown solid (34%) is obtained.
  • 1H NMR (CDCl3, 400 MHz): δ 8.42 (s, 1H), 8.26 (d, 1H, J=7.6 Hz), 7.78 (bs, 1H), 7.76 (d, 1H, J=8.4 Hz), 7.63 (t, 1H, J=7.6 Hz), 7.54 (dd, 1H, J=2.4 and 8 Hz), 7.33-7.29 (m, 2H), 7.08 (dd, 1H, J=2.4 and 7.2 Hz), 3.60 (s, 2H).
    • From 4-bromobenzene-1,2-diamine
  • To a stirred suspension of diamine (0.5 mmol; 94 mg; 1 equiv.) in toluene (2 mL) was added β-ketoester (0.5 mmol; 1 equiv.). The mixture was stirred at reflux (120° C.) during 3 hours. The mixture was diluted with EtOAc, acidified (pH 5), extracted with EtOAc, filtered, evaporated and washed with Et2O to give the expected compound.
    • Preparation of (E)-7-bromo-4-m-tolyl-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 182)
  • From ethyl 3-oxo-3-m-tolylpropanoate, a brown solid (28%) is obtained.
  • 1H NMR (CDCl3, 400 MHz): δ 7.89 (m, 3H), 7.40-7.32 (m, 4H), 3.58 (s, 2H), 2.44 (s, 3H).
  • ESI+MS: calcd for C16H13BrN2O: 328.02; found: 328.9 (MH+)
    • Preparation of (E)-7-bromo-4-(3-methoxyphenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 183)
  • From ethyl 3-(3-methoxyphenyl)-3-oxopropanoate, a brown solid (10%) is obtained.
  • ESI+MS: calcd for C16H13BrN2O2: 344.02; found: 344.9 (MH+)
    • Preparation of (E)-7-bromo-4-(3-nitrophenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 184)
  • From 3-(3-nitrophenyl)-3-oxopropanoate, a brown solid (6.5%) is obtained.
  • ESI+MS: calcd for C15H10BrN3O3: 358.99; found: 359.8 (MH+)
    • Preparation of (E)-7-bromo-4-(3-chlorophenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 185)
  • From ethyl 3-(3-chlorophenyl)-3-oxopropanoate, a brown solid (23%) is obtained.
  • ESI+MS: calcd for C15H10BrClN2O: 347.97; found: 348.8 (MH+)
    • Preparation of (E)-7-bromo-4-(3-bromophenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 186)
  • From ethyl 3-(3-bromophenyl)-3-oxopropanoate, a brown solid (10%) is obtained.
  • ESI+MS: calcd for C15H10Br2N2O: 391.92; found: 392.8 (MH+)
    • Preparation of (E)-7-bromo-4-(3-(trifluoromethyl)phenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 187)
  • From ethyl 3-(3-(trifluoromethyl)phenyl)-3-oxopropanoate, a brown solid (29%) is obtained.
  • ESI+MS: calcd for C16H10BrF3N2O: 381.99; found: 382.8 (MH+)
  • Function Imine Reduction
  • Figure US20110201601A1-20110818-C00069
    • From benzo[e][1,4]diazepin:
  • Figure US20110201601A1-20110818-C00070
  • To a stirred solution of benzo[e][1,4]diazepin (1 eqv.) in MeOH was added BH3CN-resin (3 eqv.) and AcOH. The mixture was stirred 3 days at room temperature, filtered, washed with methanol, evaporated and purified by appropriate method if necessary.
    • Preparation of 4,5-dihydro-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (compound 169)
  • Figure US20110201601A1-20110818-C00071
  • From (Z)-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (compound 162), this compound is obtained with a yield=60%
  • 1H NMR (CDCl3, 400 MHz): δ 9.12 (s, 1H), 7.35-6.67 (m, 9H,), 5.21 (s, 1H), 3.35-3.25 (q, 2H, J=10-14.8 Hz), 3.21 (s, 1H).
  • ESI+MS: calcd for C15H14N2O: 238.11; found: 239 (MH+)
    • Preparation of 7-chloro-4,5-dihydro-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one compound 171))
  • Figure US20110201601A1-20110818-C00072
  • From (Z)-7-chloro-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (compound 170), this compound is obtained with a yield=55%
  • 1H NMR (CDCl3, 400 MHz): δ 9.15 (s, 1H), 7.40-6.86 (m, 8H), 5.20 (s, 1H), 3.45-3.36 (q, 2H, J=10-13.6 Hz), 3.10 (s, 1H).
  • ESI+MS: calcd for C15H13ClN2O: 272.07; found: 273 (MH+)
    • Preparation of 7-bromo-4,5-dihydro-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (compound 164)
  • Figure US20110201601A1-20110818-C00073
  • From (Z)-7-bromo-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one (compound 163), this compound is obtained with a yield=52%
  • 1H NMR (CDCl3, 400 MHz,): δ 8.48 (s, 1H), 7.52-6.86 (m, 8H), 5.18 (s, 1H), 3.45-3.35 (q, 2H, J=10-14.8 Hz), 2.86 (s, 1H).
  • ESI+MS: calcd for C15H13BrN2O: 316.02; found: 317 (MH+)
    • From benzo[b][1,4]diazepin
  • Figure US20110201601A1-20110818-C00074
  • To a stirred solution of benzo[b][1,4]diazepin (1 eqv.) in MeOH was added BH3CN-resin (3 eqv.) and AcOH. The mixture was stirred 3 days at room temperature, filtered, washed with methanol, evaporated and purified by appropriate method if necessary.
    • Preparation of 4,5-dihydro-4-phenyl-1H-benzo[b][1,4]diazepin-2(3H)-one compound 166)
  • Figure US20110201601A1-20110818-C00075
  • From (E)-4-phenyl-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 165), this product is obtained with a yield=77%
  • 1H NMR (CDCl3, 400 MHz,): δ 9.15 (s, 1H), 7.40-6.72 (m, 9H), 5.76 (s, 1H), 4.91-4.89 (m, 1H), 2.54-2.52 (d, 2H, J=6 Hz).
  • ESI+MS: calcd for C15H14N2O: 238.11; found: 239 (MH+)
  • N-substitution
  • Figure US20110201601A1-20110818-C00076
    • Preparation of ethyl 2,3,4,5-tetrahydro-4-oxo-2-phenylbenzo[b][1,4]diazepine-1-carboxylate (compound 168)
  • Figure US20110201601A1-20110818-C00077
  • From 4,5-dihydro-4-phenyl-1H-benzo[b][1,4]diazepin-2(3H)-one (compound 165), this product is obtained with a yield=21%
  • 1H NMR (CDCl3, 400 MHz): δ 9.10 (s, 1H), 7.62-6.72 (m, 9H) 5.10 (s, 1H), 4.24 (m, 2H), 2.62-2.61 (d, 2H, J=6 Hz), 1.46 (t, 3H, J=8 Hz).
  • ESI+MS: calcd for C18H18N2O3: 310.13; found: 311 (MH+)
    • EXAMPLE 2 Biological Activity of Compounds According to the Invention
  • Materials
  • STxB-Sulf2, STxB-KDEL-Cy3, Cy3-STxB, Cy5-STxB, anti-TfR, mAb H68.4 and anti-STxB mAb 13C4 were prepared as previously described in Johannes and Goud, 1998 Trends Cell Biol 8(4): 158-62; Mallard et al. 1998 J Cell Biol 16;143(4):973-90).
  • The following products were kindly provided by the indicated colleagues: plasmid GFP-Rab11 (Kazuhisa Nakayama, Kyoto University, Japan), CTR433 (Michel Bornens, Institut Curie, France), anti-Vps26 antibody (Juan Bonifacino, Bethesda, Md., USA), anti-VSVG antibody (Franck Perez, Institut Curie, France), Stx1 (Lynne Roberts, University of Warwick, UK), ricin (Bruno Beaumelle, UMR 5539 CNRS, Montpellier, France).
  • The following products were purchased from the indicated commercial sources: 125I-EGF, 35S-sulfate, 35S-methionine (Perkin Elmer); Alexa488-conjugated CTxB (Molecular Probes); PPMP (Calbiochem), DMSO, BFA, Stx2, 2-mercaptoethanesulfonic acid sodium salt, iodoacetamide, human diferric Tf (Sigma); horseradish peroxidase-conjugated streptavidin (Roche); NHS-SS-Biotin (Pierce). The following commercial antibodies were utilized in this study: anti-giantin (Abcam), anti-TfR (BD Biosciences), anti-EEA1 (Santa Cruz), anti-Lamp1 (BD Biosciences), anti-GFP (Roche), anti-TGN46 (AbD Serotech), anti-golgin-97 (Invitrogen), anti-GM130 (Santa Cruz), anti-mouse-Alexa488, anti-goat-Alexa488, anti-rabbit-Alexa488 (Molecular Probes), and anti-sheep-Cy3 (Jackson ImmunoResearch).
  • Methods
  • 1.HELA-Cells are Protected Against STX-Intoxication
  • HeLa-cells were treated with 20 μM of compounds 161 or 193 before challenging them for 45 minutes at 37° C. with increasing doses of Stx1 and Stx2. Protein biosynthesis was determined 1 hour later by measuring the incorporation of radiolabeled methionine into acid-precipitable material.
  • Cells were washed three times with PBS and incubated in PBS containing 20 μCi/ml 35S-methionine for 60 min. Labelled proteins were precipitated with 5% (w/v) trichioroacetic acid, the wells were washed three times with PBS and the amount of radiolabel incorporated was determined after the addition of 200 μl of scintillation fluid, by scintillation counting in a Micro-Beta 1450 Trilux counter.
  • Compound-treated cells are dramatically protected against the intoxication by Stxs. In inhibitor-treated HeLa-cells, 50-100× higher doses of Stxs are needed to obtain a similar level of protein biosynthesis inhibition as in control cells (FIG. 1).
  • 2. Quantification of the Retrograde Transport Inhibition of STX to the Trans-Golgi-Network (TGN) I
  • The retrograde transport of StxB to the TGN was quantified by sulfation assay (extensively described by Amessou et al. ((2006) Curr Protoc Cell Biol Chapter 15, Unit 15 10) as early as 20 min and up to 4 h after internalization. For this assay, a StxB variant called StxB-Sulf2, which bears a tandem of protein sulfation recognition sites, is internalized in the presence of 35SO4 2−. Upon arrival in the TGN, the TGN-localized sulfotransferase catalyzes the transfer of radioactive sulphate onto StxB-Sulf2. After cell lysis, immunoprecipitation, and gel electrophoresis, [35S]-sulfated StxB-Sulf2 can be detected and quantified by autoradiography.
  • On compounds 161 or 193-treated cells, the retrograde transport of STxB is dramatically reduced (90%) (FIG. 2). Even 4 h after internalization, compounds reduce transport of StxB to the TGN by 50%.
  • 3. Transport of STX and CTX is Inhibited at the Interface Between Early Endosomes and Golgi Apparatus Immunofluorescence was used to determine at which step the retrograde transport of Stx and Ctx is inhibited. Compound-treated cells were incubated with Cy3-STxB (0.5 μg/mL) or Alexa488-CTxB (4 μg/mL) for 30 min on ice, followed by 45 min at 37° C. in the continued presence of compounds (20 μM). Cells were fixed with paraformaldehyde, and stained with compartment-specific antibodies such as EEA1, TfR, Vps26 (early endosomes), Rab11 (recycling endosomes), Lamp1 (late endosomes) and giantin (Golgi). Cells were imaged using a Leica TCS SP2 confocal microscope with HCX PL APO-objectives (100×/1.40-0.7 and 63×/1.32-0.60, Leica Microsystems, Mannheim, Germany).
  • Upon compounds-treatment, STxB accumulates in early endosomes, and the retrograde transport of CTxB and STxB to the TGN is markedly reduced (FIGS. 3 and 4).
    • 4. Cytotoxicity of Compounds 161 and 193
  • For our studies on HeLa-cells, both compounds 161 and 193 were used at a final concentration of 20 μM (0.1% DMSO). Under this condition, the effect on protein biosynthesis after 2.5 h of treatment was only minor (FIG. 1, control versus compound-treated cells at infra-toxic toxin concentrations). The cell number was determined over 3 days of treatment and compound-treatment had no influence on cell growth.
  • 5. Effects of Compounds 161 and 193 on Cellular Morphology
  • Cells were incubated with 20 μM of compound for 2 h, fixed with PFA and permeabilized with saponin. Antibodies directed against various cellular compartments were used for immunofluorescence to visualize the effect of compounds on early endosomes (EEA1, TfR), late endosomes/lysosomes (Lamp1), Golgi apparatus (giantin, golgin-97, CTR433, GM130) and the ER. For the ER-staining, the following protocol was applied: internalization of STxB-KDEL-Cy3 in the absence of inhibitors for 4 h. During this time, STxB-KDEL-Cy3 accumulates in the ER. Then, cells were treated for 2 h with DMSO, Compound 161 or Compound 193.
  • No difference between control and compound-treated cells could be observed. Also, the overall organelles and cellular morphologies were unaltered (FIG. 5). Thus, the inhibition of Stxs trafficking by Compounds 161 and 193 is most likely not due to any unspecific, general effect on the cellular integrity as seen for other inhibitors of the retrograde route.
  • 6. Effects of Compounds 161 and 193 on Lysosomal Degradation
  • In order to determine the effect of the compounds on the degradation of endocytosed cargos along the degradative (lysosomal) pathway, 125I-EGF was used as a tracer. HeLa-cells were pre-treated with the compounds 161 and 193, prior to incubation with 125I-EGF on ice for 30 min. After several washing steps, the cells were shifted to 37° C. in the presence of compounds. The radioactivity in TCA-insoluble and TCA-soluble fractions was quantified by scintillation after various time-points between 0-240 min.
  • Data from control and compound-treated cells were identical, suggesting that compounds 161 and 193 have no effect on lysosomal degradation (FIG. 6).
  • 7. Effects of Compounds 161 and 193 on the Anterograde (Secretory) Pathway
  • The effect of compounds 161 and 193 was quantitatively determined by measuring the secretion of vesicular stomatitis virus G protein (VSVG) in control and inhibitors-treated cells (Amessou et al (2007) J Cell Sci 120, 1457-1468). Cells were transfected with GFP-VSVGts045 and incubated overnight at 40° C. Under these conditions, the protein accumulates in the endoplasmic reticulum. Transport to the Golgi complex and plasma membrane is initiated by shifting cells to 32° C., and expression at the plasma membrane is quantified by FACS using an anti-VSVG antibody.
  • The anterograde transport of GFP-VSVGts045 was not significantly reduced upon treatment with compounds 161 and 193 in contrast to brefeldin A. The results show that compound 161 and 193 block the retrograde pathway only but not the anterograde secretion route (FIG. 7).
  • 8. Toxin Binding on Cells
  • The amount of bound StxB on cells was not reduced by compound 161 or 193, as quantified by FACS.
  • HeLa-cells were compound-treated (30 min, 37° C., 20 μM), incubated on ice with STxB-Cy5 (1 μM) for 30 min, washed three times in 3% FCS/PBS, and analyzed by FACS (FACSCalibur). The fluorescence intensity corresponds to bound STxB-Cy5 on HeLa cells. 20.000 cells were analyzed for each condition. As a negative control, Gb3-depleted HeLa cells were used. For this, HeLa-cells were treated for 6 days with 5 μM of the glucosylceramide synthase inhibitor 1-phenyl-2-hexadecanoyl-amino-3-morpholino-1-propanol (PPMP).
  • 9. Toxin Uptake in Presence of Compounds 161 and 193
  • The endocytosis of StxB and transferrin (Tf) was not altered after the treatment with both compounds 161 or 193. For demonstrating this, cells were compound-treated (20 μM, 30 min, 37° C.), incubated on ice with StxB or Tf that are linked via a reducible disulfide bond to biotin (StxB-SS-Biotin and Tf-SS-Biotin). After washing, cells are incubated at 37° C. for different times. Biotin on surface-exposed STxB-SS-Biotin or Tf-SS-Biotin was cleaved by subsequent treatment with the non-membrane-permeable reducing agent MESNA (2-mercaptoethansulfonic acid). Under these conditions, internalized StxB-SS-Biotin and Tf-SS-Biotin are protected from the reduction. After inactivation of MESNA by addition of iodoacetamide (150 mM) and cell lysis, biotinylated STxB and Tf were quantified by ELISA using anti-STxB mAb 13C4, anti-Tf mAb H68.4 and streptavidin-HRP
  • StxB and Tf are similarly internalized into control and compound-treated cells (FIGS. 8 and 9).
  • 10. Effect of Compounds 161 and 193 on Retrograde Transport of Endogenous Cargos (TGN46, CI-M6PR)
  • To characterize the inhibitory effect of compounds on endogenous cargos, the transport of either CI-M6PR or TGN46 was compared between compound-treated and control cells. HeLa-cells over-expressing MPR-GFP were pretreated with 20 μM of compounds 193 or 161 for 30 min at 37° C. (FIG. 10A). After binding of STxB-Cy3, cells were incubated with anti-GFP antibody for 40 min at 37° C. During this time, the antibody binds to cell-surface MPR-GFP, and the MPR-GFP/anti-GFP antibody-complex is internalized and transported to the Golgi apparatus, where it colocalizes with Giantin, a Golgi-marker. Note, that in compound-treated cells, where the retrograde transport of STxB to the TGN is inhibited, the MPR-GFP/anti-GFP antibody-complex is still transported efficiently to the Golgi, suggesting that the two compounds are cargo-specific (i.e. no effect on MPR-transport).
  • HeLa-cells were treated for 5.5 h at 37° C. with 20 μM of compounds 193 or 161 (FIGS. 10B and 10C). After binding of STxB-Cy3 on ice, cells were incubated for another 45 min at 37° C. in the presence of compounds 193 or 161, fixed and stained for the indicated antibodies. Note that the steady-state localization of CI-MPR and TGN46 is similar under control and compound-treatment conditions. These results suggest, that both compounds have no effect on the transport of both proteins, and thus on their steady-state localization.
  • It has not been observed a distinct inhibition of the transport of CI-M6PR and TGN46 induced by either compounds 161 or 193, further substantiating the specificity of both compounds towards exogenous toxins. This finding is highly surprising as to date all trafficking factors that have been found to be required for Shiga toxin transport have also been shown to be required for mannose 6-phosphate transport, when this was directly tested (Amessou et al., 2007). The finding that compounds 161 and 193 inhibit Shiga toxin trafficking without affecting mannose 6-phosphate transport is therefore highly unexpected.
  • 11. Compounds 161 and 193 Effects are Robust and Observed on Others Human Cell Lines
  • Besides HeLa-cells, human monocytic, Gb3-expressing THP1-cells were used to characterize the inhibitory effect of the compounds. Concentrations of up to 100 μM of compounds did not cause any reduction in the overall protein biosynthesis. By using immunofluorescence, THP1-cells were incubated with 100 μM of compound for 30 min at 37° C., before binding of StxB on ice for 30 min and internalization for 45 mn at 37° C. Fixed cells were stained for the Golgi-marker giantin.
  • In line with the effect observed on HeLa-cells, a stark reduction of retrograde transport of StxB to the TGN was observed on THP1-cells treated with compounds 161 or 193. This suggests that the effect of these compounds is not restricted to a single cell-line, but can be observed on cells as diverse as epithelial HeLa-cells and monocytic THP1-cells.
    • CONCLUSION
  • In the case of Stxs, after treatment with compounds 161 or 193 of toxin-sensitive HeLa-cells, a 50-100× higher dose of toxin is necessary to cause a similar inhibitory effect on protein-biosynthesis as on control cells. This effect is attributed to an inhibition in the retrograde transport of the toxin at the interface between early endosomes and Golgi apparatus, and it is not due to a reduction in toxin binding or internalization, or an unspecific effect on cellular morphology or functional alteration of cellular compartments. The transport of StxB to the trans-Golgi network was reduced by 60-90%, as verified by sulfation assay. Compound-treatment of cells leads to an accumulation of StxB and CtxB in early endosomes. The effect of these compounds is confined to retrograde transport and does not affect other transport pathways, e.g. anterograde (secretory) or late endosomal (degradative) pathway. Even though these compounds impair the transport of exogenous toxins, Inventors unexpectedly did not observe a pronounced effect on endogenous cargos, such as CI-M6PR (cation-independent mannose-6-phosphate receptor) or TGN46. Long-term treatment up to 3 days does not reduce cellular growth. On THP-1-cells, compounds 161 and 193 concentrations as high as 100 μM did not cause any apparent side effects.
  • In contrast to others small molecules, compounds 161 and 193 are specific to exogenous toxins (Shiga and cholera toxins) and they unexpectedly do not impact distinctly the transport of endogenous cargo (CI-M6PR, TGN46). Additionally, these compounds do no have any effect on the morphology of cellular compartments and do not influence cellular growth even after longer treatments (several days). Also, their effect is restricted to the retrograde transport route and does not influence anterograde transport, degradation or endocytosis.

Claims (18)

1. A method of preparing a drug, the method comprising:
combining (A1) an imine derivative compound of formula (I):
Figure US20110201601A1-20110818-C00078
wherein:
X is —NH— or —O—;
R1 is a cycloalkyl radical having 5 to 10 carbon atoms, having one or two rings, saturated or not, wherein one or more carbon atom is optionally replaced by a nitrogen, oxygen or sulfur atom, and wherein said cycloalkyl radical is optionally substituted by at least one substituent selected from the group consisting of a halogen atom, a hydroxyl function, a nitro function, and a C1-C3 alkyl group;
R2 is a hydrogen atom or a link and when R2 is a link, the nitrogen atom to which R2 is bonded forms a double bond with the adjacent non-aromatic carbon atom;
and/or (A2) a pharmaceutically acceptable salt of the imine derivative compound,
with (B) a pharmaceutically acceptable carrier,
wherein the drug is suitable for preventing and/or treating disorders caused by a Shiga toxin or a related toxin.
2. The method according to claim 1, wherein the compound of formula (I) is at least one selected from the group consisting of:
2-(3-bromobenzylideneamino)-N-phenylbenzamide;
2-(3-bromobenzylamino)-N-phenylbenzamide;
2-(3-fluorobenzylideneamino)-N-phenylbenzamide;
(E)-2-((furan-2-yl)methyleneamino)-N-phenylbenzamide;
(E)-2-((furan-3-yl)methyleneamino)-N-phenylbenzamide;
(E)-2((5-methylfuran-2-yl)methyleneamino)-N-phenylbenzamide;
(E)-2-(5-fluoro-2-nitrobenzylideneamino)-N-phenylbenzamide;
(E)-2-(4-fluorobenzylideneamino)-N-phenylbenzamide;
(E)-2(2-fluorobenzylideneamino)-N-phenylbenzamide;
(E)-2-((1-methyl-1H-indol-2-yl)methyleneamino)-N-phenylbenzamide;
(E)-2-(5-bromo-2-hydroxybenzylideneamino)-N-phenylbenzamide;
2-(2-fluorobenzylamino)-N-phenylbenzamide; and
(E)-2-(2-(5-methylthiophen-2-yl)vinyl)-N-phenylbenzamide.
3. A method of preparing a drug, the method comprising:
combining (A1) a benzodiazepine derivative compound of formula (II):
Figure US20110201601A1-20110818-C00079
wherein:
A and B are a carbon atom or a nitrogen atom, with the proviso that when A=N then B═C and when A=C then B═N;
R3 is a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a C3-C6 alkoxy group, a C1-C6 acyloxy group, an aryloxy group, or a heteroaryloxy group, these groups being optionally substituted by a C1-C6 alkoxy group or a heteroaryloxy group;
R4 is either a link or a hydrogen atom, a C1-C3 acyloxy group, a C1-C3 alkoxy group, or a phenyl group;
R5 is either a link or a hydrogen atom, a C1-C3 alkoxy group, a C1-C3 acyloxy group, a C1-C3 alkyl group, saturated or not, optionally substituted by a phenyl group, or a phenyl group which is optionally substituted by at least one radical selected from the group consisting of —OH, a halogen atom, a C1-C3 alkyl group, a C1-C3 alkoxy group, —NO2, —CF3, and
Figure US20110201601A1-20110818-C00080
with the proviso that R4 and R5 can not simultaneously be a link and when R4 or R5 is a link then A and B are linked by a double bound,
or R5 optionally, together with the carbon atom in the α-position to B, forms a cycle of 5 or 6 atoms optionally substituted by a phenyl radical, and optionally interrupted by a nitrogen, oxygen, or sulfur atom;
R6 is an oxygen atom or one or two C1-C3 alkyl groups;
and/or (A2) a pharmaceutically acceptable salt of the benzodiazepine derivative compound,
with (B) a pharmaceutically acceptable carrier,
wherein the drug is suitable for preventing and/or treating disorders caused by a Shiga toxin or a related toxin.
4. The method according to claim 3, wherein the compound of formula (II) is at least one selected from the group consisting of:
5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one;
7-bromo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one;
7-bromo-5-phenyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-one;
4-phenyl-2,3-dihydro-1H-1,5-benzodiazepin-2-one;
4-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-one;
4,5-dihydro-7-methoxy-5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one;
ethyl 4-oxo-2-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carboxylate;
5-phenyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-one;
7-chloro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one;
7-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-one;
4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one;
4-(5-bromo-2-hydroxyphenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one;
4-(5-fluoro-2-hydroxyphenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one;
8-bromo-3-phenyl-3,3a,5,10-tetrahydrobenzo[b]pyrrolo[2,3-e][1,4]diazepin-4(2H)-one;
4-m-tolyl-1H-benzo[b][1,4]diazepin-2(3H)-one;
4-(3-methoxyphenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one;
4-(3-nitrophenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one;
4-(3-chlorophenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one;
4-(3-bromophenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one;
4-(3-(trifluoromethyl)phenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one
7-bromo-4-m-tolyl-1H-benzo[b][1,4]diazepin-2(3H)-one;
7-bromo-4-(3-methoxyphenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one;
7-bromo-4-(3-nitrophenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one;
7-bromo-4-(3-chlorophenyl)-1H-benzo [b][1,4]diazepin-2(3H)-one;
7-bromo-4-(3-bromophenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one;
7-bromo-4-(3-(trifluoromethyl)phenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one;
7-bromo-2,2,4-trimethyl-2,3-dihydro-1H-benzo[b][1,4]diazepine;
(E)-7-bromo-2,2-dimethyl-4-styryl-2,3-dihydro-1H-benzo[b][1,4]diazepine;
(E)-7-bromo-4-(3-bromostyryl)-2,2-dimethyl-2,3-dihydro-1H-benzo[b][1,4]diazepine; and
7-bromo-5-phenyl-4-propionyl-4,5-dihydro-1H-benzo[e][1,4]diazepin-2(3H)-one,
5. The method according to claim 1, wherein the Shiga toxin or related toxin comprises:
the Shiga toxin (Stx) produced by Shigella dysenteriae;
Shiga-like toxin 1 and 2 (SLT-1 and 2 or Stx-1 and 2 or Verotoxin 1 and Verotoxin 2) produced Shigatoxigenic group of Escherichia coli (STEC); or
cholera toxin (Ctx).
6. The method according to claim 1, wherein the disorder is at least one selected from the group consisting of abdominal pain, nausea, vomiting, diarrhea, watery diarrhea, bloody diarrhea, a complication of hemolytic uremic syndrome (HUS) selected from the group consisting of microangiocytopenia anemia, thrombocytopenia) and nephropathy, and an extra-renal complication of HUS selected from the group consisting of seizure, intracranial infarction, intracranial hemorrhage, retinal hemorrhage, retinal encephalopathy, acute pancreatitis, and cardiomyopathy.
7. A method of treating a disorder caused by a Shiga toxin or a related toxin, the method comprising administering to a subject in need thereof, an affective amount of a drug obtained by the method of claim 1.
8. A method of treating a disorder caused by a Shiga toxin or a related toxin, the method comprising administering to a subject in need thereof, an effective amount of a drug obtained by the method of claim 2.
9. A method of treating a disorder caused by a Shiga toxin or a related toxin, the method comprising administering to a subject in need thereof, an effective amount of a drug obtained by the method of claim 3.
10. A method of treating a disorder caused by a Shiga toxin or a related toxin, the method comprising administering to a subject in need thereof, an effective amount of a drug obtained by the method of claim 4.
11. The method according to claim 7, wherein the disorder is at least one selected from the group consisting of abdominal pain, nausea, vomiting, diarrhea, watery diarrhea, bloody diarrhea, a complication of hemolytic uremic syndrome (HUS) selected from the group consisting of microangiocytopenia anemia, thrombocytopenia, and nephropathy, and an extra-renal complication of HUS selected from the group consisting of seizure, intracranial infarction, intracranial hemorrhage, retinal hemorrhage, retinal encephalopathy, acute pancreatitis, and cardiomyopathy.
12. The method according to claim 8, wherein the disorder is at least one selected from the group consisting of abdominal pain, nausea, vomiting, diarrhea, watery diarrhea, bloody diarrhea, a complication of hemolytic uremic syndrome (HUS) selected from the group consisting of microangiocytopenia anemia, thrombocytopenia, and nephropathy, and an extra-renal complication of HUS selected from the group consisting of seizure, intracranial infarction, intracranial hemorrhage, retinal hemorrhage, retinal encephalopathy, acute pancreatitis, and cardiomyopathy.
13. The method according to claim 9, wherein the disorder is at least one selected from the group consisting of abdominal pain, nausea, vomiting, diarrhea, watery diarrhea, bloody diarrhea, a complication of hemolytic uremic syndrome (HUS) selected from the group consisting of microangiocytopenia anemia, thrombocytopenia, and nephropathy, and an extra-renal complication of HUS selected from the group consisting of seizure, intracranial infarction, intracranial hemorrhage, retinal hemorrhage, retinal encephalopathy, acute pancreatitis, and cardiomyopathy.
14. The method according to claim 10, wherein the disorder is at least one selected from the group consisting of abdominal pain, nausea, vomiting, diarrhea, watery diarrhea, bloody diarrhea, a complication of hemolytic uremic syndrome (HUS) selected from the group consisting of microangiocytopenia anemia, thrombocytopenia, and nephropathy, and an extra-renal complication of HUS selected from the group consisting of seizure, intracranial infarction, intracranial hemorrhage, retinal hemorrhage, retinal encephalopathy, acute pancreatitis, and cardiomyopathy.
15. The method according to claim 7, wherein the Shiga toxin or related toxin comprises:
the Shiga toxin (Stx) produced by Shigella dysenteriae;
Shiga-like toxin 1 and 2 (SLT-1 and 2 or Stx-1 and 2 or Verotoxin 1 and Verotoxin 2) produced Shigatoxigenic group of Escherichia coli (STEC); or
cholera toxin (Ctx).
16. The method according to claim 8, wherein the Shiga toxin or related toxin comprises:
the Shiga toxin (Stx) produced by Shigella dysenteriae;
Shiga-like toxin 1 and 2 (SLT-1 and 2 or Stx-1 and 2 or Verotoxin 1 and Verotoxin 2) produced Shigatoxigenic group of Escherichia coli (STEC); or cholera toxin (Ctx).
17. The method according to claim 9, wherein the Shiga toxin or related toxin comprises:
the Shiga toxin (Stx) produced by Shigella dysenteriae;
Shiga-like toxin 1 and 2 (SLT-1 and 2 or Stx-1 and 2 or Verotoxin 1 and Verotoxin 2) produced Shigatoxigenic group of Escherichia coli (STEC); or
cholera toxin (Ctx).
18. The method according to claim 10, wherein the Shiga toxin or related toxin comprises:
the Shiga toxin (Stx) produced by Shigella dysenteriae;
Shiga-like toxin 1 and 2 (SLT-1 and 2 or Stx-1 and 2 or Verotoxin 1 and Verotoxin 2) produced Shigatoxigenic group of Escherichia coli (STEC); or
cholera toxin (Ctx).
US12/999,749 2008-06-17 2009-06-17 Inhibitors of the Shiga toxins trafficking through the retrograde pathway Expired - Fee Related US8609732B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/083,690 US9034868B2 (en) 2008-06-17 2013-11-19 Inhibitors of the shiga toxins trafficking through the retrograde pathway

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08290570 2008-06-17
EP08290570A EP2145873A1 (en) 2008-06-17 2008-06-17 New compounds with activity that protects against the action of toxins and viruses in intracellular action mode
EP08290570.4 2008-06-17
PCT/IB2009/006334 WO2009153665A2 (en) 2008-06-17 2009-06-17 Inhibitors of the shiga toxins trafficking through the retrograde pathway

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/006334 A-371-Of-International WO2009153665A2 (en) 2008-06-17 2009-06-17 Inhibitors of the shiga toxins trafficking through the retrograde pathway

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/083,690 Division US9034868B2 (en) 2008-06-17 2013-11-19 Inhibitors of the shiga toxins trafficking through the retrograde pathway

Publications (2)

Publication Number Publication Date
US20110201601A1 true US20110201601A1 (en) 2011-08-18
US8609732B2 US8609732B2 (en) 2013-12-17

Family

ID=40070650

Family Applications (5)

Application Number Title Priority Date Filing Date
US12/999,749 Expired - Fee Related US8609732B2 (en) 2008-06-17 2009-06-17 Inhibitors of the Shiga toxins trafficking through the retrograde pathway
US12/999,576 Abandoned US20120283249A1 (en) 2008-06-17 2009-06-17 Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action
US14/083,690 Expired - Fee Related US9034868B2 (en) 2008-06-17 2013-11-19 Inhibitors of the shiga toxins trafficking through the retrograde pathway
US14/810,342 Abandoned US20160083355A1 (en) 2008-06-17 2015-07-27 Compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action
US15/494,798 Abandoned US20170233386A1 (en) 2008-06-17 2017-04-24 Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/999,576 Abandoned US20120283249A1 (en) 2008-06-17 2009-06-17 Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action
US14/083,690 Expired - Fee Related US9034868B2 (en) 2008-06-17 2013-11-19 Inhibitors of the shiga toxins trafficking through the retrograde pathway
US14/810,342 Abandoned US20160083355A1 (en) 2008-06-17 2015-07-27 Compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action
US15/494,798 Abandoned US20170233386A1 (en) 2008-06-17 2017-04-24 Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action

Country Status (3)

Country Link
US (5) US8609732B2 (en)
EP (4) EP2145873A1 (en)
WO (2) WO2009153665A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123217A1 (en) * 2012-02-16 2013-08-22 The University Of North Carolina At Chapel Hill Small molecules that enhance the activity of oligonucleotides
US9675615B2 (en) 2012-10-19 2017-06-13 Commissariat A L'energie Atomique Et Aux Energies Alternatives 2,3-dihydroquinazolin-4(1H)-one derivatives for use in the treatment of viral infections
US9695156B2 (en) 2012-07-16 2017-07-04 Brown University Compounds for the treatment and prevention of infections
US20190016715A1 (en) * 2014-06-10 2019-01-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
RU2702359C1 (en) * 2019-06-04 2019-10-08 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Method of producing 2,2,4-trialkyl-2,3-dihydro-1h-1,5-benzodiazepines
WO2024064200A3 (en) * 2022-09-20 2024-05-16 The Texas A&M University System Darpin-containing compositions and methods thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229045A1 (en) * 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
WO2010043953A2 (en) * 2008-10-15 2010-04-22 Orchid Research Laboratories Ltd. Novel bridged cyclic compounds as histone deacetylase inhibitors
US20120100609A1 (en) * 2009-03-27 2012-04-26 Crawford Brett E N-linked glycan biosynthesis modulators
US9884832B2 (en) * 2011-12-06 2018-02-06 The Trustees Of The University Of Pennsylvania Inhibitors targeting drug-resistant influenza A
EP2722328A1 (en) 2012-10-19 2014-04-23 Commissariat A L'energie Atomique Et Aux Energies Alternatives Novel compounds with protective activity against toxins with intracellular action mode
CN102942590B (en) * 2012-11-01 2015-12-16 武汉三聚生物技术有限公司 α-(diamantane) aminophosphonic acid and its production and use
CN104844532A (en) * 2014-02-19 2015-08-19 周敬业 Antiviral compounds, and preparation method and use thereof
CN106029635A (en) * 2014-02-28 2016-10-12 海蔻有限公司 Novel economic process for vildagliptin
CN104447687B (en) * 2014-11-18 2016-09-14 王志训 A kind of industrial process of nitrogenous heptatomic ring derivant
US10039727B2 (en) * 2015-04-21 2018-08-07 Commissariat A L'energie Atomique Et Aux Energies Alternatives Adamantane or pinene derivatives for use in the treatment of chlamydiales infections
US11136299B2 (en) * 2015-04-21 2021-10-05 Commissariat A L'energie Atomique Et Aux Energies Alternatives Benzodiazepine derivatives for use in the treatment of Chlamydiales infections
CN107663159A (en) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 Polycyclic compound, its pharmaceutical composition and application
EP3476389A1 (en) * 2017-10-31 2019-05-01 Commissariat à l'Energie Atomique et aux Energies Alternatives Adamantane or bicyclic monoterpenoid derivatives for use in the treatment of leishmaniasis
RU2702358C1 (en) * 2019-06-04 2019-10-08 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Method of producing 2,2,4-trialkyl-2,3-dihydro-1h-1,5-benzodiazepines
WO2021252099A2 (en) * 2020-05-04 2021-12-16 Virginia Commonwealth University Antimicrobial and antitoxin compositions and methods for treatment
US11987543B1 (en) 2023-10-31 2024-05-21 King Faisal University 8-(4-bromobenzylideneamino)naphthalene-1,3-disulfonic acid as an antioxidant compound
US11932593B1 (en) 2023-10-31 2024-03-19 King Faisal University 8-(3-bromobenzylideneamino)naphthalene-1,3-disulfonic acid as an antioxidant compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177280B1 (en) * 1996-12-24 2001-01-23 Xinjian Yan Ricin inhibitors and methods for use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3216969A (en) * 1961-10-27 1965-11-09 Universal Oil Prod Co Polymers stabilized with o-hydroxybenzalaminodiphenylamines or metal coordination complexes thereof
DE1594841A1 (en) * 1966-01-14 1970-07-23 Bayer Ag Whitening agents
GB1181520A (en) * 1966-10-18 1970-02-18 Delmar Chem Substituted 1-Aminoadamantanes
GB1198853A (en) * 1967-06-13 1970-07-15 Squibb & Sons Inc Adamante Derivatives
FR1552840A (en) * 1967-06-26 1969-01-10
AT329813B (en) * 1973-07-03 1976-05-25 Siegwart Emil FLOW REGULATOR FOR AIR PIPES
DE2403138A1 (en) * 1974-01-23 1975-07-31 Hoechst Ag BENZYLAMINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
US5321047A (en) * 1988-06-03 1994-06-14 John Wyeth & Brother, Limited Method and amines used therein
US6562969B1 (en) * 1996-12-24 2003-05-13 Research Development Foundation Ricin inhibitors and methods for use thereof
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
MXPA01011052A (en) * 1999-04-30 2002-11-22 Univ Michigan Therapeutic applications of pro-apoptotic benzodiazepines.
GB0126901D0 (en) * 2001-11-08 2002-01-02 Novartis Ag Organic compounds
US6869787B2 (en) 2002-02-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Ricin vaccine and methods of making and using thereof
DE102004001871A1 (en) * 2004-01-14 2005-09-01 Bayer Healthcare Ag Tricyclic benzazepine derivatives and their use
DE102004054545A1 (en) * 2004-09-16 2006-04-06 Max-Delbrück-Centrum für Molekulare Medizin Change in the loading state of MHC molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177280B1 (en) * 1996-12-24 2001-01-23 Xinjian Yan Ricin inhibitors and methods for use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RN 143424-08-2, 1992(Abstract only) *
Yongquing et al, Synthetic Comm., 2004, 34(17), 3235-3242. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123217A1 (en) * 2012-02-16 2013-08-22 The University Of North Carolina At Chapel Hill Small molecules that enhance the activity of oligonucleotides
US9695156B2 (en) 2012-07-16 2017-07-04 Brown University Compounds for the treatment and prevention of infections
US9675615B2 (en) 2012-10-19 2017-06-13 Commissariat A L'energie Atomique Et Aux Energies Alternatives 2,3-dihydroquinazolin-4(1H)-one derivatives for use in the treatment of viral infections
US20190016715A1 (en) * 2014-06-10 2019-01-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
US10597367B2 (en) * 2014-06-10 2020-03-24 Sanford Burnham Prebys Medical Discovery Institute Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
US11447453B2 (en) 2014-06-10 2022-09-20 Sanford Burnham Prebys Medical Discovery Institute Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
RU2702359C1 (en) * 2019-06-04 2019-10-08 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Method of producing 2,2,4-trialkyl-2,3-dihydro-1h-1,5-benzodiazepines
WO2024064200A3 (en) * 2022-09-20 2024-05-16 The Texas A&M University System Darpin-containing compositions and methods thereof

Also Published As

Publication number Publication date
US20140073633A1 (en) 2014-03-13
EP2296757A2 (en) 2011-03-23
US9034868B2 (en) 2015-05-19
US20120283249A1 (en) 2012-11-08
WO2009153665A2 (en) 2009-12-23
WO2009153457A2 (en) 2009-12-23
US20160083355A1 (en) 2016-03-24
EP2297088A2 (en) 2011-03-23
US20170233386A1 (en) 2017-08-17
WO2009153457A3 (en) 2010-07-29
WO2009153665A3 (en) 2010-04-08
EP3239131A1 (en) 2017-11-01
US8609732B2 (en) 2013-12-17
EP2145873A1 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
US8609732B2 (en) Inhibitors of the Shiga toxins trafficking through the retrograde pathway
US11155561B2 (en) Substituted glutarimides as Btk inhibitors
US20210340105A1 (en) Aminopyridine compounds and methods for the preparation and use thereof
US11180459B2 (en) Bacterial efflux pump inhibitors
US12006294B2 (en) Therapeutic compounds
US9540356B2 (en) Compounds having a protective activity against toxins with intracellular activity
US20090286829A1 (en) Quinolynylmethylimidizoles as therapeutic agents
KR20200030584A (en) compound
AU2020273443A1 (en) Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2
US10093658B2 (en) Bifunctional compounds and use for reducing uric acid levels
US9814719B2 (en) Methods and compositions for treating bacterial infection
US20250109142A1 (en) Therapeutic compounds and methods
US10441588B2 (en) Methods and compositions for treating bacterial infection
US20160229841A1 (en) Novel beta lactams as modulators of glutamate uptake and methods for use thereof
US9845296B2 (en) Benzimidazoles and their use in the treatment of tuberculosis
EP3661912B9 (en) Compounds for treating infections
US20230293539A1 (en) Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
US9598381B2 (en) SMYD2 inhibitors
US20230348365A1 (en) Compounds for treating infections
US10954197B2 (en) Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer
WO2014113607A1 (en) Protective molecules against anthrax toxin
PL198759B1 (en) Novel benzimidazoles and benzoxazoles

Legal Events

Date Code Title Description
AS Assignment

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GILLET, DANIEL;BARBIER, JULIEN;JOHANNES, LUDGER;AND OTHERS;SIGNING DATES FROM 20110110 TO 20110114;REEL/FRAME:026021/0936

Owner name: INSTITUT CURIE, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GILLET, DANIEL;BARBIER, JULIEN;JOHANNES, LUDGER;AND OTHERS;SIGNING DATES FROM 20110110 TO 20110114;REEL/FRAME:026021/0936

Owner name: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GILLET, DANIEL;BARBIER, JULIEN;JOHANNES, LUDGER;AND OTHERS;SIGNING DATES FROM 20110110 TO 20110114;REEL/FRAME:026021/0936

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.)

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20171217

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载